-
is dependent on studies of active interferon-gamma signaling in dendritic cells
Time of Update: 2022-05-19
>Some of the pathways by which dendritic cells promote chronic immune activation are induced by the production of IL-23 and IL12 . The IL-23 cytokine consists of two subunits, IL23A (IL-23p19
-
Cancer Cell: Revealing the mechanism of arachidonic acid and interferon-gamma synergistically induce ferroptosis in tumor cells
Time of Update: 2022-04-29
In a new study, researchers from the University of Michigan's Roger Cancer Center found that a cytokine and a fatty acid work synergistically to trigger a type of cell death previously identified by studies of synthetic molecules .
-
ARD: Points to be considered for the diagnosis and management of autoinflammatory type I interferon
Time of Update: 2022-04-24
RESULTS: The working group developed consensus and evidence-based guidelines on 4 overarching principles and 17 points for the diagnosis, treatment and long-term monitoring of patients with autoinflammatory interferon disease CANDLE/PRAAS , SAVI and AGS .
-
ARD: Anifrolumab efficacy and safety according to type I interferon gene signature and clinical
Time of Update: 2022-04-23
Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials.
-
ARD: Anti-RNP antibodies in systemic lupus erythematosus are associated with an interferon gene signature independent of reduced complement levels
Time of Update: 2022-04-18
To elucidate the interrelationship of specific antinuclear antibodies (ANA) , complement and interferon gene signature (IGS) in the pathogenesis of systemic lupus erythematosus (SLE) .
-
ARD: A phase II randomized trial of the type I interferon inhibitor anivolumab in patients with active lupus nephritis
Time of Update: 2022-04-16
Conclusions: Although the primary endpoint was not met, in patients with active lupus nephritis, anifrugumab IR improved endpoint values including complete renal response at 52 weeks compared with placebo .
-
ARD: Aging and interferon gamma responses drive a neutrophilic phenotype in inflamed joints
Time of Update: 2022-04-16
neutrophils migrate from the blood to the joints . Methods: We performed RNA - sequencing
-
A&R: Induction of interferon-gamma and tissue inflammation by overexpression of eosinophil cationic protein in T cells and exosomes
Time of Update: 2022-02-19
RESULTS: We identified eosinophil cationic protein ( ECP , also known as human RNase III ) overexpressed in SLE T cell-derived exosomes .
-
Clin Exp Immunol: Interferon-Gamma- and perforin-positive T cells in acquired aplastic anemia predict response to immunosuppressive therapy
Time of Update: 2022-01-23
of T lymphocytes in the bone marrow and destruction of hematopoietic stem cells by effector cells . Interferon
-
ARD: B cell depletion impairs the CD8+ T cell response induced by vaccination in a type I interferon-dependent manner
Time of Update: 2022-01-07
Objective: monoclonal anti- CD20 antibody rituximab is often used in the treatment of lymphoma and self- immune diseases, can effectively remove circulating B cells .
-
A&R: The enhancement of interferon gene stimulating factor induces the production of type I interferon in COPA syndrome
Time of Update: 2021-12-25
In vitro analysis showed that COPA V242G and previously reported pathogenic mutations enhanced the type I IFN promoter activity induced by stimulus of interferon gene (STING) .
-
FDA renews approval of the first interferon for the treatment of polycythemia vera
Time of Update: 2021-12-07
On November 12, 2021, the US Food and Drug Administration (FDA) approved Besremi (ropeginterferon alfa-2b-njft) injection to treat adult patients with polycythemia vera (a blood disease that causes excessive red blood cell production) .
-
Science Advances Zhejiang University Qing Zhou/Xiamin Yu discovered a new regulatory mechanism for type I interferon production
Time of Update: 2021-12-06
In this study, it was demonstrated that IFN-I was activated in primary cells of patients with otulipenia, and the proteasome component was identified as a substrate for OTULIN-mediated linear deubiquitination .
-
61% of patients achieve complete remission, FDA approves the first polycythemia vera interferon drug
Time of Update: 2021-12-02
Recently, PharmaEssentia announced that the US FDA has approved the long-acting interferon Besremi (ropeginterferonα-2b-njft) to be marketed for the treatment of adult patients with polycythemia vera (PV) .
-
Xuetao Cao’s team discovered a new molecule lncRNA-ISIR that enhances the effect of interferon
Time of Update: 2021-11-14
, interested parties can Long press or scan the QR code below to follow us . iNature Interferon Regulatory Factor 3 (IRF3) is an important transduction factor that initiates many immune
-
Clinical trial found that interferon does not help hospitalized adults with new coronary pneumonia
Time of Update: 2021-11-04
In this study, Remdesivir is still used as an active control because the first iteration of the ACTT trial found that antiviral drugs are better than placebo in reducing the recovery time of COVID-19 hospitalized patients .
-
The acute increase of ALT during interferon treatment is related to the decrease of HBsAg!
Time of Update: 2021-10-11
published a study to evaluate the relationship between acute elevation of alanine aminotransferase (ALT) and serum hepatitis B surface antigen (HBsAg) and HBV RNA dynamics in CHB patients receiving PEG IFNα therapy.
-
Nat Nanotechnol: construction of T lymphocyte membrane modified interferon epigenetic nanoinducer
Time of Update: 2021-10-10
of OPEN. The enhanced effect increased the infiltration of CTLs in tumors by 29 times, significantly reduced the immune side effects of ORY-1001 (Figure 1C), and effectively inhibited the growth of triple-negative breast cancer, melanoma
-
INFECTION: The level of plasma interferon-γ-inducible protein 10 (IP-10) in humans is correlated with the severity of extrapulmonary tuberculosis
Time of Update: 2021-09-28
The results of the study found that compared with healthy controls, patients with tuberculosis external pulmonary phenotypic disease had significantly increased plasma IP-10 levels (p <0.
-
What is the effect of interferon in the treatment of new crowns?
Time of Update: 2021-08-05
In another part of the patients, because the early new coronavirus suppressed the release of interferon, when the virus invaded the lungs in large quantities, the human body would initiate a rapid immune response to fight against it .
